This is a Phase 2 clinical study in patients with actinic keratosis involving daily application of 1 of 2 strengths of VDA-1102 topical ointment for approximately 12 weeks (84 days). This study has no placebo and the subjects enrolled in the study will know exactly what they are receiving. The objectives of the study are to evaluate the safety and benefit of these two strengths.

Start Date23 May 2018

Sponsor / Collaborator

Vidac Pharma Ltd.

[+3]

NCT02844777 / CompletedPhase 2

Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Once-Daily Application of Topical VDA-1102 Ointment for 28 Days in Subjects With Actinic Keratosis

This Phase 2 clinical trial is a multi-center, randomized, double-blind, placebo-controlled, multiple-dose, parallel-cohort study to assess the efficacy, safety and tolerability of VDA-1102 in the treatment of actinic keratosis (AK) on the head of male and female adult subjects.

Start Date15 Jul 2016

Sponsor / Collaborator

Vidac Pharma Ltd.

100 Clinical Results associated with Vidac Pharma Ltd.

0 Patents (Medical) associated with Vidac Pharma Ltd.

Literatures (Medical) associated with Vidac Pharma Ltd.

01 Dec 2018·Journal of Investigative DermatologyQ1 · MEDICINE

A Hexokinase 2 Modulator for Field-Directed Treatment of Experimental Actinic Keratoses

Q1 · MEDICINE

Article

Author: Herzberg, Max ; Kozminsky-Atias, Adi ; Becker, Oren M ; Arbel, Nir ; Loeb, Emmanuel ; Behar, Vered ; Pahima, Hadas

Overexpression of hexokinase 2, and its binding to VDAC1 on the outer mitochondrial membrane of cancer cells, is key to their metabolic reprogramming to aerobic glycolysis, which enables them to proliferate. We describe Comp-1, an allosteric small molecule that selectively detaches hexokinase 2 from the mitochondria. Detachment of hexokinase 2 reduces glycolysis and triggers apoptosis in cancer cells, without affecting hexokinase 1-expressing normal cells. The anti-cancer activity of Comp-1 was demonstrated in the UVB-damaged skin model in SKH-1 mice. Topical treatment with Comp-1 led to 70% reduction in lesion number and area. This in vivo efficacy was obtained without local skin reactions or other safety findings. Mechanism-related pharmacodynamic markers, including hexokinase 2 and cleaved caspase 3 levels, are affected by Comp-1 treatment in vivo. Good Laboratory Practice toxicology studies in minipigs for 28 days and 13 weeks established no systemic toxicities and minimal dermal reaction for once-daily application of up to 20% and 15% ointment strengths, respectively. Thus, Comp-1 may address a significant unmet medical need for a non-irritating efficacious topical actinic keratosis treatment.

01 Jul 2018·Cancer Research

Abstract 1725: A bi-functional mechanism of action: Activating the NLRP3 inflammasome and triggering apoptosis in cancer via a HK2-VDAC modulator

Author: Becker, Oren M. ; Dor-On, Eyal ; Hamo, Reut Yosef ; Behar, Vered

AbstractIntroduction: Cancer cells undergo metabolic reprogramming to enable the efficient conversion of glucose needed for massive cell growth and proliferation, a well-documented phenomenon known as the Warburg effect. A key enzyme in this process is hexokinase 2 (HK2), which catalyzes the first step of glucose metabolism. Unlike HK1, which is ubiquitously expressed in normal cells, high levels of HK2 are found in cancer where it is required for cancer initiation and transformation. HK2 in cancer cells is attached to the outer mitochondrial membrane via the VDAC1 channel. VDAC1/HK2 association blocks pro-apoptotic signals as well as allows a continuous flux of mitochondrial ATP to HK, leading to apoptosis prevention and a high rate of glycolysis.Temporal high HK2 expression, and binding to VDAC, is also found in a variety of activated immune cells to support their changing metabolic needs. It has been recently published that detachment of HK2 from VDAC is one of the first events leading to the NLRP3-inflammasome activation, resulting in IL-1β and IL-18 secretion from macrophages (Cell 166:624 (2016)).Methods: A novel small molecule VDAC/HK2 modulator, VDA-1102, is being developed as a bi-functional drug for the treatment of solid tumors – triggering apoptosis in cancer cells while simultaneously activating the NLRP3-inflammasome in macrophages to induce an anti-tumoral immune response.Results: In vitro studies established that VDA-1102 selectively detaches HK2, but not HK1, from VDAC leading to cancer cell apoptosis, glycolysis inhibition, and prevention of cancer cell proliferation. VDA-1102 treatment of mouse primary bone marrow-derived macrophages and of human macrophage cell line, THP-1 cells, established a dose-dependent NLRP3-inflammasome activation and cytokine secretion. In vivo efficacy studies demonstrated significant tumor growth delay in syngeneic solid tumor models.Analysis of tumor-associated macrophages indicated a treatment-induced change in these macrophage phenotype from M2 to M1. This change was associated with a notable increase in spleen size, an increase ratio of naïve T cell in the spleen, and a significant increase in CD8+ and CD4+ tumor-infiltrating T cells.Conclusions: This data supports the notion that VDA-1102 is a bi-functional drug that targets both cancer and the innate immune system. In cancer cells it induces apoptosis, whereas in macrophages it activates the NLRP3-inflammasome machinery and stimulates an anti-tumor immune response. Our findings support further development of VDA-1102 to evaluate its potential as an anti-cancer therapy, either as a monotherapy or in combination with checkpoint inhibitors in high HK2-expressing solid tumors.Citation Format: Vered Behar, Reut Yosef Hamo, Eyal Dor-On, Oren M. Becker. A bi-functional mechanism of action: Activating the NLRP3 inflammasome and triggering apoptosis in cancer via a HK2-VDAC modulator [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1725.

A novel chemical entity, that reverses Warburg metabolism by disrupting VDAC1/HK2 interaction through “Toposteric Effect” in Cancer

Author: Becker, Oren M. ; Yosef, Reut ; Herzberg, Max ; de Conto, Veronique ; Pahima, Hadas ; Behar, Vered ; Sagiv, Yuval ; Maubon, Nathalie ; Dor-On, Eyal

Abstract

Background Acidic pH and low oxygen levels Due to the Warburg effect have been shown to impart resistance to certain anti-cancer therapies for solid tumors, such as radiation and a variety of chemotherapeutic drugs. Cancer immunotherapy represents one of the most exciting advancements in recent cancer therapy. However, despite these achievements, the numbers of patients with effective cure are very low for patients with solid tumors. Recent studies pointed out that the main cause for this low efficiency is the Tumor microenvironment (TME), with metabolic changes, and immune evasion that renders solid tumor eradication a real challenge. Drugs targeting the inhibitory TME are urgently needed in combination with Immunotherapy, as well as other conventional therapies like chemotherapy and cancer targeted growth blockers. Methods In this study we used an inhibitor of Hexokinase-2 binding to the mitochondrial VDAC1 channel (VDA-1275), that is shown to block cancer cell proliferation, induce apoptosis in cancer cells, and change TME from a protumor to a pro-immunological environment. Our studies demonstrate a significant tumor growth inhibition and survival prolongation, combined with a strong safety profile in-vivo. In addition, a powerful synergistic anti-cancer effect was demonstrated, using a 3D cell culture with human hepatic cancer cell organoids, when VDA-1275 was combined with low levels of Cisplatin or Sorafenib, as examples for chemotherapy and targeted therapy treatments, respectively. Results Our results suggest that VDA-1275 is a novel compound that effect cancer cells directly and indirectly by changing the TME to a pro-immunogenic environment. Conclusion VDA-1275 may be used as a standalone drug, or in combination therapy that will allow more effective and safe treatment of patients with solid tumors. We coined the word and concept of “Toposteric” effect as the use of small molecules or peptides which interact with a receptor or ligand binding site avoiding the possibility of a pro-pathological harmful anchoring without affecting its active site.

News (Medical) associated with Vidac Pharma Ltd.

27 Mar 2024

·www.globenewswire.com

Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate

Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate London (UK), March 27, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces it has received a Notice of Allowance from the Japanese Patent Office for the composition and methods of use for its VDA-1275 drug candidate, which has shown multiple promising effects in preclinical studies. “Receiving this notice from the Japanese authorities adds to our excitement about VDA-1275, Vidac’s next and powerful anti-cancer drug candidate. In recent preclinical studies, this new molecule has shown effects, both directly against a variety of tumors in animal trials, and through powerful synergistic effects in combination with two widely used types of chemotherapy in human liver organoids,” Vidac Pharma Chief Executive Officer Max Herzberg said. Last month, Vidac announced results showing that VDA-1275 statistically significantly increased survival in a murine colorectal cancer model as a stand-alone treatment, with a survival benefit similar to Opdivo in a head-to-head comparison. In a 3-D organoid model of human liver cancer, it reduced the concentrations of sorafenib and cisplatin needed to achieve IC50 cancer cell viability by 50% and 95%, respectively. Finally, VDA-1275 triggered an immune response through several mechanisms. The company will publish these results in a peer-reviewed publication. Both VDA-1275 and the more advanced VDA-1102, which is in separate Phase 2 testing of advanced actinic keratosis and of cutaneous T cell lymphoma, disrupt the interaction between hexokinase 2 (HK2) and the voltage-dependent anion channels (VDACs) in mitochondria. Cancer cells overexpress HK2, which catalyzes the first step of the glucose metabolism necessary to fuel tumor growth. HK2 blocks VDACs, which prevents apoptosis, supports cancer cell proliferation, and suppresses immune responses. Clinical data for Vidac’s first-generation metabolic checkpoint modulator candidates have shown powerful effects in halting cancer cell proliferation and restoring immune-sensitivity and apoptosis. For more information please contact: Vidac Pharma Holding PlcDr Max Herzberg20-22 Wenlock RoadLondon N1 7GUUnited Kingdomhttp://www.vidacpharma.com/investors@vidacpharma.com+972-54-4257381+972-77-9300647Cohesion BureauGiovanni Ca’ ZorziInvestor Relationsgiovanni.cazorzi@cohesionbureau.comSophie BaumontMedia Relations sophie.baumont@cohesionbureau.com About Vidac Pharma Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK) and interim results in Cutaneous T-cell Lymphoma (CTCL) gave positive effect in Phase 2 trials in humans.www.vidacpharma.com Important information The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. Attachment 20240327 - VIDAC PR Japan patent VDA1275

Clinical ResultPhase 2

29 Jan 2024

·pipelinereview.com

Vidac Pharma reports positive interim Phase 2a data in orphan disease cutaneous T-cell lymphoma (CTCL) with lead asset VDA-1102

LONDON, UK I January 29, 2024 I Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking new way of treating cancer, today announces favorable findings from a Phase 2a interim analysis of its lead drug candidate VDA-1102 in Mycosis Fungoides (MF), a form of Cutaneous T-Cell Lymphoma (CTCL) and a rare “orphan” disease which might command fast-track regulatory processing . The data provide further signs of the efficacy and safety of Vidac Pharma’s family of non-toxic small molecules in treating cancer. The interim analysis of 50% of subjects showed an Objective Response Rate (ORR) of 56%, with 22% complete response (CR), and 34% partial response. Responses were observed between 8 and 12 weeks. These results compare favorably to the standard of care of mechlorethamine, which has a 13% CR and a much longer median response time of 26 weeks. Side-effects were local and mild in severity, except in one case, which was moderate. All patients recovered, however, and the disease did not progress in any of the patients during the 4 months of the study. “These interim results are another important confirmation that Vidac Pharma’s approach of attacking cancer at its core has substantial therapeutic potential. Our drug candidates reverse the abnormal metabolism that is a characteristic of all cancer cells, halting tumor proliferation and immune-resistance. What we are seeing bears the promise of applying these drugs across a wide range of cancers,” said Vidac Pharma Chief Executive Officer Max Herzberg. The interim results come from more than 50% of planned patients - 9 out of 16 – in an open-label within-subject placebo-controlled study into the efficacy and safety of VDA-1102 as a topical ointment treatment for 12 weeks in adult subjects with relapsed stage-1 MF. Next milestones are full-population interim results, expected in the second quarter, and final results in Q4. Vidac Pharma is developing a breakthrough new technology which reverses the abnormal metabolism of cancer cells – known as the Warburg effect - by preventing the Hexokinase 2 (HK2) enzyme from blocking the VDAC mitochondrial relay channels. Clinical data have shown the powerful effects this can have in halting cancer cell proliferation and restoring programmed cell death. Vidac’s lead drug candidate VDA-1102 is also at the clinical development stage for patients with actinic keratosis (AK), for which the company will soon launch a second Phase 2b study. About Vidac Pharma Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma was proven effective against advanced Actinic Keratosis (AK) and Cutaneous T-cell Lymphoma (CTCL) in Phase 2 trials in humans. www.vidacpharma.com SOURCE: Vidac Pharma

Phase 2Clinical Result

19 Oct 2022

·www.prnewswire.com

Non-melanoma Skin Cancer Market size to grow by USD 180.97 Mn with 36% of the growth to originate from North America - Technavio

NEW YORK, Oct. 19, 2022 /PRNewswire/ -- According to the research report, the Non-melanoma Skin Cancer Market will witness a YOY growth of 5.41 % in 2022 at a CAGR of 5.76% during the forecast period. The report is segmented by type (BCC and SCC) and geography (North America, Europe, Asia, and Rest of World (ROW)). For more insights on YOY and CAGR, Read FREE Sample Report. Continue Reading Technavio has announced its latest market research report titled Global Non-melanoma Skin Cancer Market 2022-2026 Non-melanoma Skin Cancer Market - Major Vendors Non-melanoma Skin Cancer Market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. Vendors are being driven by the intensifying market rivalry to implement a variety of growth methods, such as promotional efforts and spending on advertising, to increase the exposure of their services. In order to remain competitive in the market, several suppliers are also implementing inorganic expansion tactics like M&As. The report analyzes the market's competitive landscape and offers information on several market vendors, including: 3M Corp. Almirall SA Amgen Inc. Bausch Health Companies Inc. Bristol Myers Squibb Co. Elekta AB Eli Lilly and Co. F. Hoffmann La Roche Ltd. GlaxoSmithKline Plc iCAD Inc. Merck and Co. Inc. Find additional highlights on the growth strategies adopted by vendors and their product offerings, Buy Sample Report . Non-melanoma Skin Cancer Market - Geographical Analysis One of the most prevalent malignancies in the US is skin cancer. It is responsible for between 35% and 45% of all malignancies in Caucasians. The most prevalent form of cancer in the US and Canada is NMSC. During the projected period, the strong prevalence of BCC is anticipated to play a significant role in the market's expansion in the area. Numerous organizations in North America, including the Skin Cancer Foundation and the American Academy of Dermatology (AAD), launch projects and campaigns to raise public awareness of the prevention and early detection of skin cancer. During the anticipated period, these variables are anticipated to fuel market expansion. Furthermore, countries such as the US, Canada, UK, Germany, Japan, and China are expected to emerge as prominent markets for Non-melanoma Skin Cancer Market during the forecast period. Download Free Sample Report. Non-melanoma Skin Cancer Market - Key Segment Analysis The BCC segment's market share rise in non-melanoma skin cancer will be high. About 80% of NMSC is made up of BCC. According to estimates, the incidence of BCC has been increasing by 5% annually in Europe and 2% annually in the US during the previous few years. Australia has the greatest proportion of BCC patients who have received a diagnosis by the age of 70 in APAC. Surgical procedures have become more common in recent years, and both the general public and doctors are becoming more aware of BCC. Despite having a low death rate, BCCs can cause significant physical damage. Non-melanoma Skin Cancer Market - Key Drivers & Challenges The NMSC coverage and support is one of the major drivers fueling growth in the non-melanoma skin cancer market. Direct medical expenses for treating NMSC include pathology fees, facility fees, diagnosis fees, treatment fees, repair fees, and other incidentals. Medicare and the majority of payers reimburse the costs of Mohs surgery, excision, and destruction as part of treatment. Compared to surgery, the majority of pharmacological techniques demand significant effort and several doctor visits. Most of the medications for NMSC are paid for by the manufacturing business in the form of patient support and discount vouchers for low-income populations. However, the market for non-melanoma skin cancer will face significant challenges due to the small number of NMSC-specific medicines in development. Get a free sample for highlights on market Drivers & Challenges affecting the Non-melanoma Skin Cancer Market. Related Reports: Polycystic Kidney Disease Drugs Market by Type and Geography - Forecast and Analysis 2022-2026: The high prevalence of chronic kidney diseases is notably driving the polycystic kidney disease drugs market growth. The report extensively covers polycystic kidney disease drugs market segmentation by type (ADPKD and ARPKD) and geography (North America, Europe, Asia, and Rest of World (ROW)). Breast Cancer Therapeutics Market by Product and Geography - 2022-2026: The rising prevalence of breast cancer is notably driving the breast cancer therapeutics market growth. The report extensively covers the breast cancer therapeutics market segmentation by product (targeted therapy, hormonal therapy, and chemotherapy) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). Table of Contents 1 Executive Summary 1.1 Market Overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Type Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Type 5.1 Market segments Exhibit 24: Chart on Type - Market share 2021-2026 (%) Exhibit 25: Data Table on Type - Market share 2021-2026 (%) 5.2 Comparison by Type Exhibit 26: Chart on Comparison by Type Exhibit 27: Data Table on Comparison by Type 5.3 BCC - Market size and forecast 2021-2026 Exhibit 28: Chart on BCC - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on BCC - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on BCC - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on BCC - Year-over-year growth 2021-2026 (%) 5.4 SCC - Market size and forecast 2021-2026 Exhibit 32: Chart on SCC - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on SCC - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on SCC - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on SCC - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Type Exhibit 36: Market opportunity by Type ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Canada - Market size and forecast 2021-2026 Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.9 UK - Market size and forecast 2021-2026 Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.10 Germany - Market size and forecast 2021-2026 Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.11 Japan - Market size and forecast 2021-2026 Exhibit 74: Chart on Japan - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on Japan - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on Japan - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on Japan - Year-over-year growth 2021-2026 (%) 7.12 China - Market size and forecast 2021-2026 Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%) 7.13 Market opportunity by geography Exhibit 82: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 83: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 84: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 85: Overview on factors of disruption 9.4 Industry risks Exhibit 86: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 87: Vendors covered 10.2 Market positioning of vendors Exhibit 88: Matrix on vendor position and classification 10.3 3M Corp. Exhibit 89: 3M Corp. - Overview Exhibit 90: 3M Corp. - Business segments Exhibit 91: 3M Corp. - Key news Exhibit 92: 3M Corp. - Key offerings Exhibit 93: 3M Corp. - Segment focus 10.4 Almirall SA Exhibit 94: Almirall SA - Overview Exhibit 95: Almirall SA - Product / Service Exhibit 96: Almirall SA - Key news Exhibit 97: Almirall SA - Key offerings 10.5 Bausch Health Companies Inc. Exhibit 98: Bausch Health Companies Inc. - Overview Exhibit 99: Bausch Health Companies Inc. - Business segments Exhibit 100: Bausch Health Companies Inc. - Key news Exhibit 101: Bausch Health Companies Inc. - Key offerings Exhibit 102: Bausch Health Companies Inc. - Segment focus 10.6 Bristol Myers Squibb Co. Exhibit 103: Bristol Myers Squibb Co. - Overview Exhibit 104: Bristol Myers Squibb Co. - Product / Service Exhibit 105: Bristol Myers Squibb Co. - Key offerings 10.7 Elekta AB Exhibit 106: Elekta AB - Overview Exhibit 107: Elekta AB - Business segments Exhibit 108: Elekta AB - Key news Exhibit 109: Elekta AB - Key offerings Exhibit 110: Elekta AB - Segment focus 10.8 F. Hoffmann La Roche Ltd. Exhibit 111: F. Hoffmann La Roche Ltd. - Overview Exhibit 112: F. Hoffmann La Roche Ltd. - Business segments Exhibit 113: F. Hoffmann La Roche Ltd. - Key news Exhibit 114: F. Hoffmann La Roche Ltd. - Key offerings Exhibit 115: F. Hoffmann La Roche Ltd. - Segment focus 10.9 Mylan N.V Exhibit 116: Mylan N.V - Overview Exhibit 117: Mylan N.V - Product / Service Exhibit 118: Mylan N.V - Key offerings 10.10 Sun Pharmaceutical Industries Ltd. Exhibit 119: Sun Pharmaceutical Industries Ltd. - Overview Exhibit 120: Sun Pharmaceutical Industries Ltd. - Product / Service Exhibit 121: Sun Pharmaceutical Industries Ltd. - Key offerings 10.11 Varian Medical Systems Inc. Exhibit 122: Varian Medical Systems Inc. - Overview Exhibit 123: Varian Medical Systems Inc. - Business segments Exhibit 124: Varian Medical Systems Inc. - Key offerings Exhibit 125: Varian Medical Systems Inc. - Segment focus 10.12 Vidac Pharma Exhibit 126: Vidac Pharma - Overview Exhibit 127: Vidac Pharma - Product / Service Exhibit 128: Vidac Pharma - Key offerings 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 129: Inclusions checklist Exhibit 130: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 131: Currency conversion rates for US$ 11.4 Research methodology Exhibit 132: Research methodology Exhibit 133: Validation techniques employed for market sizing Exhibit 134: Information sources 11.5 List of abbreviations Exhibit 135: List of abbreviations About Us: Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website:  SOURCE Technavio

100 Deals associated with Vidac Pharma Ltd.

100 Translational Medicine associated with Vidac Pharma Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Tuvatexib ( HK2 x VDAC1 )	Actinic Keratosis More	Phase 2
VDA-1275 ( HK2 )	Solid tumor More	Preclinical
VDA-1214 ( HK2 )	Solid tumor More	Discontinued
VDA-1270 ( HK2 )	Solid tumor More	Discontinued

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis